Efficacy of biphasic insulin aspart in patients with type 2 diabetes

Clinical Therapeutics
Serge HalimiGao Yan

Abstract

It is estimated that 39% of people with diabetes worldwide who use insulin are prescribed premixes, largely because of the practical advantages of addressing both prandial and basal insulin needs with a single product. Rapid-acting premixed insulin analogues such as biphasic insulin aspart 30 (BIAsp 30 [30% soluble insulin aspart and 70% protamine-crystallized insulin aspart], NovoLog Mix 70/30, Novo Nordisk, Bagsvaerd, Denmark) have been developed recently to overcome the pharmacokinetic limitations of regular human insulin used in the most commonly prescribed premix, biphasic human insulin 30 (BHI 30, 30% human insulin and 70% neutral protamine Hagedorn [NPH] insulin). It would be expected that these pharmacokinetic improvements would enhance clinical performance. However, the efficacy of BIAsp 30 compared with other common treatment regimens has not yet been systematically reviewed. The aim of this paper is to review current data on the efficacy of BIAsp 30 in comparison with other treatment strategies in type 2 diabetes, including oral antidiabetic drugs (eg, metformin, sulfonylureas, meglitinides, thiazolidinediones), conventional insulins (eg, BHI 30, NPH insulin), and other analogue insulins (eg, insulin glargine, biphas...Continue Reading

References

Nov 11, 1991·Archives of Internal Medicine·D S BellL Wagenknecht
Oct 6, 1997·Endocrinology and Metabolism Clinics of North America·M C Riddle
Apr 30, 1999·Diabetes Research and Clinical Practice·H Overmann, L Heinemann
Oct 8, 1999·Diabetic Medicine : a Journal of the British Diabetic Association
Jun 15, 2000·European Journal of Clinical Pharmacology·H E Turner, D R Matthews
Sep 29, 2000·European Journal of Clinical Pharmacology·L V JacobsenA Riis
Sep 12, 2001·Lancet·D R OwensG B Bolli
May 25, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·B O BoehmA Lindholm
Aug 14, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·S Heller
Apr 10, 2003·Mayo Clinic Proceedings·Jean L Chan, Martin J Abrahamson
Jun 11, 2003·Archives of Internal Medicine·John E Gerich
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Mar 12, 2004·The American Journal of Medicine·Matthew C Riddle
Apr 20, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·C KapitzaL Heinemann
Sep 15, 2004·Diabetes Research and Clinical Practice·Mark L WarrenElsie Allen
Nov 20, 2004·Diabetes/metabolism Research and Reviews·Rüdiger Landgraf
Dec 25, 2004·Diabetes Care·UNKNOWN American Diabetes Association
Jan 26, 2005·European Journal of Internal Medicine·Bernhard O BoehmPhilip D Home
Jan 29, 2005·Diabetes Care·Philip RaskinUNKNOWN INITIATE Study Group
Feb 19, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·J-W ChenJ S Christiansen
Mar 25, 2005·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·I SchmoelzerT C Wascher

❮ Previous
Next ❯

Citations

Nov 17, 2009·Reviews in Endocrine & Metabolic Disorders·Ahmet KorkmazRussel J Reiter
Oct 16, 2010·Advances in Therapy·Walid K H FakhouryTorsten E Christensen
Jul 13, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jihad HaddadPradana Soewondo
Mar 14, 2013·Diabetes Research and Clinical Practice·UNKNOWN International Diabetes Federation Guideline Development Group
May 27, 2008·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Antonio CerielloUNKNOWN Guideline Development Group
Jul 9, 2016·BMC Endocrine Disorders·Sylvie ErpeldingerRémy Boussageon
Nov 28, 2017·Current Medical Research and Opinion·Chaicharn DeerochanawongUnchalee Permsuwan
Dec 27, 2019·American Journal of Therapeutics·Helena W Rodbard, David Rodbard
Jun 18, 2011·Postgraduate Medicine·Jeff Unger, Christopher Parkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.